GPT and type 2 diabetes mellitus: Key studies include the e-LIFT study (2018), whereby Empagliflozin (10 mg) significantly reduced liver fat by 16.2% compared to 11.3% in the placebo group, thus improving liver enzymes (ALT) [172]; the study carried out by Kahl et al., which reported that Empagliflozin (25 mg) reduced liver fat content in T2D patients with MASLD, confirmed by magnetic resonance spectroscopy [173]; Shimizu et al.’s study, which reported dapagliflozin (5 mg/day) to result in significant reductions in liver fat and liver stiffness, which was investigated by transient elastography [174].